To ask the Secretary of State for Health and Social Care, whether she plans to review the eligibility criteria for antivirals for those suffering from long covid.

Decisions on the eligibility criteria for treatment with antivirals are made by the National Institute for Health and Care Excellence (NICE), based on an assessment of their costs and benefits, developed in line with marketing authorisations issued by the Medicines and Healthcare products Regulatory Agency.

The NICE has published guidance that recommends the antivirals Paxlovid, Veklury, and Lagevrio for the treatment of COVID-19, both in the community, and for patients in hospital. This guidance sets out the eligibility criteria and ensures that patients who are at the highest risk of developing severe disease from COVID-19 have access to clinically and cost-effective treatments. Patients with long COVID have not been identified as a distinct group that would be eligible for treatment, and there are currently no licensed antivirals for the treatment of long COVID. The NICE therefore has no current plans to review the eligibility criteria in its guidance. The NICE maintains surveillance of new evidence that may affect its published guidance, and would consult on proposed changes if significant new evidence were to emerge.